• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sandoz - Articles and news items

biosimilar-etanercept

FDA committee recommends approval of Sandoz’s biosimilar etanercept

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

The Arthritis Advisory Committee voted unanimously in support of biosimilar etanercept for all five indications of the reference product…

biosimilar etanercept

Sandoz announces EGALITY trial results for biosimilar etanercept

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

The EGALITY study involved 531 patients and compared the efficacy and safety of biosimilar etanercept with the originator product, Enbrel…

biosimilar infliximab

Sandoz acquires rights to biosimilar infliximab in the EEA

Industry news / 12 February 2016 / Victoria White

Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis…

etanercept

EMA accepts MAA for Sandoz’s biosimilar etanercept

Industry news / 8 December 2015 / Victoria White

Sandoz is seeking approval for all indications included in the label of the reference product which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis…

sandoz

FDA accepts Sandoz’s BLA for biosimilar etanercept

Industry news / 2 October 2015 / Victoria White

Sandoz is seeking approval for all indications included in the label of etanercept which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis…

sandoz

Sandoz opens new state-of the-art BioInject facility in Schaftenau

Industry news / 17 September 2015 / Victoria White

BioInject will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics…

SANDOZ

Phase III data shows Sandoz’ investigational biosimilar filgrastim has similar safety and efficacy as Amgen’s NEUPOGEN®

Industry news / 8 December 2014 / Novartis

Sandoz, a Novartis company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen’s NEUPOGEN ® (filgrastim) in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy…

SANDOZ

FDA accepts Sandoz application for biosimilar filgrastim

Industry news / 24 July 2014 / Novartis

Sandoz announced that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim…

SANDOZ

Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide

Industry news / 30 June 2014 / Novartis

Sandoz announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation…

Novartis

Novartis emphasizes new focused portfolio at its first Meet Novartis Management investor day

Industry news / 18 June 2014 / Novartis

For its first “Meet Novartis Management” investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals…

SANDOZ

Sandoz begins Phase III clinical trial for biosimilar adalimumab

Industry news / 19 December 2013 / Sandoz

Sandoz advances leading biosimilars pipeline by strengthening Immunology portfolio…

SANDOZ

Sandoz launches Phase III clinical trial for biosimilar etanercept

Industry news, News / 24 June 2013 / Novartis

Sandoz has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen’s Enbrel®)…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +